1
|
Chavez MG, Buhr CA, Petrie WK, Wandinger-Ness A, Kusewitt DF, Hudson LG. Differential downregulation of e-cadherin and desmoglein by epidermal growth factor. Dermatol Res Pract 2012; 2012:309587. [PMID: 22312325 PMCID: PMC3270554 DOI: 10.1155/2012/309587] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Revised: 10/01/2011] [Accepted: 10/02/2011] [Indexed: 12/03/2022] Open
Abstract
Modulation of cell : cell junctions is a key event in cutaneous wound repair. In this study we report that activation of the epidermal growth factor (EGF) receptor disrupts cell : cell adhesion, but with different kinetics and fates for the desmosomal cadherin desmoglein and for E-cadherin. Downregulation of desmoglein preceded that of E-cadherin in vivo and in an EGF-stimulated in vitro wound reepithelialization model. Dual immunofluorescence staining revealed that neither E-cadherin nor desmoglein-2 internalized with the EGF receptor, or with one another. In response to EGF, desmoglein-2 entered a recycling compartment based on predominant colocalization with the recycling marker Rab11. In contrast, E-cadherin downregulation was accompanied by cleavage of the extracellular domain. A broad-spectrum matrix metalloproteinase inhibitor protected E-cadherin but not the desmosomal cadherin, desmoglein-2, from EGF-stimulated disruption. These findings demonstrate that although activation of the EGF receptor regulates adherens junction and desmosomal components, this stimulus downregulates associated cadherins through different mechanisms.
Collapse
Affiliation(s)
- Miquella G. Chavez
- Division of Bioengineering, Department of Physiology, University of California San Francisco, San Francisco, CA 94158, USA
| | - Christian A. Buhr
- College of Pharmacy, University of New Mexico, MSC 09 5360, Albuquerque, NM 87131, USA
| | - Whitney K. Petrie
- Department of Animal Science, University of California, Davis, CA 95616, USA
| | - Angela Wandinger-Ness
- Department of Pathology, School of Medicine, University of New Mexico, MSC 08 4640, Albuquerque, NM 87131, USA
| | - Donna F. Kusewitt
- Science Park Research Division, Department of Carcinogenesis, University of Texas, M.D. Anderson Cancer Center, Smithville, TX 78957, USA
| | - Laurie G. Hudson
- College of Pharmacy, University of New Mexico, MSC 09 5360, Albuquerque, NM 87131, USA
- Science Park Research Division, Department of Carcinogenesis, University of Texas, M.D. Anderson Cancer Center, Smithville, TX 78957, USA
| |
Collapse
|
2
|
Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi SI, Sklar SLA, Hathaway HJ, Arterburn JB, Prossnitz ER. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 2011; 127:358-66. [PMID: 21782022 PMCID: PMC3220788 DOI: 10.1016/j.jsbmb.2011.07.002] [Citation(s) in RCA: 228] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2011] [Revised: 07/01/2011] [Accepted: 07/03/2011] [Indexed: 12/16/2022]
Abstract
GPER/GPR30 is a seven-transmembrane G protein-coupled estrogen receptor that regulates many aspects of mammalian biology and physiology. We have previously described both a GPER-selective agonist G-1 and antagonist G15 based on a tetrahydro-3H-cyclopenta[c]quinoline scaffold. The antagonist lacks an ethanone moiety that likely forms important hydrogen bonds involved in receptor activation. Computational docking studies suggested that the lack of the ethanone substituent in G15 could minimize key steric conflicts, present in G-1, that limit binding within the ERα ligand binding pocket. In this report, we identify low-affinity cross-reactivity of the GPER antagonist G15 to the classical estrogen receptor ERα. To generate an antagonist with enhanced selectivity, we therefore synthesized an isosteric G-1 derivative, G36, containing an isopropyl moiety in place of the ethanone moiety. We demonstrate that G36 shows decreased binding and activation of ERα, while maintaining its antagonist profile towards GPER. G36 selectively inhibits estrogen-mediated activation of PI3K by GPER but not ERα. It also inhibits estrogen- and G-1-mediated calcium mobilization as well as ERK1/2 activation, with no effect on EGF-mediated ERK1/2 activation. Similar to G15, G36 inhibits estrogen- and G-1-stimulated proliferation of uterine epithelial cells in vivo. The identification of G36 as a GPER antagonist with improved ER counterselectivity represents a significant step towards the development of new highly selective therapeutics for cancer and other diseases.
Collapse
Affiliation(s)
- Megan K. Dennis
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
| | - Angela S. Field
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
| | - Ritwik Burai
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003
| | - Chinnasamy Ramesh
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003
| | - Whitney K. Petrie
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
| | - Cristian G. Bologa
- Division of Biocomputing, Department of Biochemistry & Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
| | - Tudor I. Oprea
- Division of Biocomputing, Department of Biochemistry & Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- UNM Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- Corresponding author: Eric R. Prossnitz; Tel: 505-272-5647; Fax: 505-272-1421;
| | - Yuri Yamaguchi
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan
| | - Shin-ichi Hayashi
- Department of Molecular and Functional Dynamics, Tohoku University, Sendai, Japan
| | - S. Larry A. Sklar
- UNM Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
| | - Helen J. Hathaway
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- UNM Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
| | - Jeffrey B. Arterburn
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003
- UNM Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- Corresponding author: Eric R. Prossnitz; Tel: 505-272-5647; Fax: 505-272-1421;
| | - Eric R. Prossnitz
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- UNM Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131
- Corresponding author: Eric R. Prossnitz; Tel: 505-272-5647; Fax: 505-272-1421;
| |
Collapse
|
3
|
Abstract
Two recent reports provide compelling insights into the role for RANK and its ligand, RANKL, in progestin-dependent mammary tumorigenesis. These findings build upon a considerable body of evidence pointing to the RANK signaling pathway as being a key mediator of progestin action in the mammary glands.
Collapse
Affiliation(s)
- Whitney K Petrie
- Department of Animal Science, University of California Davis, 2145 Meyer Hall, One Shields Avenue, Davis, CA 95616, USA
| | | |
Collapse
|
4
|
Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009; 5:421-7. [PMID: 19430488 PMCID: PMC2864230 DOI: 10.1038/nchembio.168] [Citation(s) in RCA: 409] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2008] [Accepted: 03/16/2009] [Indexed: 12/13/2022]
Abstract
Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein-coupled receptor GPR30/GPER, in addition to classical nuclear estrogen receptors (ERα/β), activates cellular signaling pathways in response to estrogen. In order to distinguish between the actions of classical estrogen receptors and GPR30, we have previously characterized a selective agonist of GPR30, G-1 (1). To complement the pharmacological properties of G-1, we sought to identify an antagonist of GPR30 that displays similar selectivity against the classical estrogen receptors. Here we describe the identification and characterization of a G-1 analog, G15 (2) that binds to GPR30 with high affinity and acts as an antagonist of estrogen signaling through GPR30. In vivo administration of G15 reveals that GPR30 contributes to both uterine and neurological responses initiated by estrogen. The identification of this antagonist will accelerate the evaluation of the roles of GPR30 in human physiology.
Collapse
Affiliation(s)
- Megan K Dennis
- Department of Cell Biology & Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|